New kid on the block: Chantix for smoking cessation.
Rankin
K Vendrell
KV
Baylor Tobacco Treatment Services, Department of Public Health Sciences, Baylor College of Dentistry, Dallas, USA.
D000284:Administration, Oral; D001552:Benzazepines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D017277:Drug Approval; D006801:Humans; D009325:Nausea / Q000139:chemically induced; D011810:Quinoxalines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011950:Receptors, Cholinergic / Q000187:drug effects; D011978:Receptors, Nicotinic / Q000187:drug effects*; D012907:Smoking / Q000009:adverse effects; D016540:Smoking Cessation / Q000379:methods*; D013375:Substance Withdrawal Syndrome / Q000209:etiology; D013607:Tablets; D000068580:Varenicline
D001552:Benzazepines; D011810:Quinoxalines; D011950:Receptors, Cholinergic; D011978:Receptors, Nicotinic; D013607:Tablets; C403531:nicotinic receptor alpha4beta2; D000068580:Varenicline